ArticleMolecular cancer therapeutics2016
Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models.
Article in Molecular cancer therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Advances in bevacizumab in colorectal cancer: a bibliometric analysis from 2004 to 2023.Frontiers in oncology · 2025Pooled it
- The Prognostic Value of Periostin Expression in Non-Small Cell Lung Cancer: A Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2022Pooled it
- Multi-omics characterization of a GPRC5AJournal of translational medicine · 2026Article
- NICD3 mediates pro-angiogenic effects through SMAD3/TGFBI axis in colorectal cancer.Cell death & disease · 2026Article
- Article
- The Expression and Oncogenic Role of NTSR2 in Human Glioblastoma.OncoTargets and therapy · 2026Article
- Periostin: A matricellular protein with a multifaceted role in tumorigenesis (Review).International journal of molecular medicine · 2025Review
- The association between periostin and tumor microenvironment: a promising cancer prognostic biomarker and therapeutic target to combat tumor progression and chemoresistance.Cancer cell international · 2025Review
- The roles of periostin derived from cancer-associated fibroblasts in tumor progression and treatment response.Cancer metastasis reviews · 2024Review
- A patient-derived cell model for malignant transformation in IDH-mutant glioma.Acta neuropathologica communications · 2024Article
- Expression of Periostin Alternative Splicing Variants in Normal Tissue and Breast Cancer.Biomolecules · 2024Article
- Monitoring melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance.Cell reports. Medicine · 2024Article
- Review
- Molecular mechanisms of tumour development in glioblastoma: an emerging role for the circadian clock.NPJ precision oncology · 2024Review
- System biology approach to identify the novel biomarkers in glioblastoma multiforme tumors by using computational analysis.Frontiers in pharmacology · 2024Article
- Transcriptional immunogenomic analysis reveals distinct immunological clusters in paediatric nervous system tumours.Genome medicine · 2023Article
- CHSY3 promotes proliferation and migration in gastric cancer and is associated with immune infiltration.Journal of translational medicine · 2023Article
- LIN28B and Let-7 in Diffuse Midline Glioma: A Review.Cancers · 2023Review
- Anti-Vascular Endothelial Growth Factor Therapy Abolishes Glioma-Associated Endothelial Cell-Induced Tumor Invasion.Journal of molecular neuroscience : MN · 2023Article
- Tumor-secreted lactate contributes to an immunosuppressive microenvironment and affects CD8 T-cell infiltration in glioblastoma.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Periostin (POSTN) interacts with multiple integrins to coordinate a variety of cellular processes, including epithelial-to-mesenchymal transition (EMT) and cell migration. In our previous study, anti-VEGF-A therapy was associated with resistance and EMT. This study sought to determine the role of POSTN in the resistance of glioma stem cells (GSC) to antiangiogenic therapy. In mouse xenograft models of human glioma, POSTN expression was associated with acquired resistance to anti-VEGF-A therapy and had a synergistic effect with bevacizumab in prolonging survival and decreasing tumor volume. Resistance to anti-VEGF-A therapy regulated by POSTN was associated with increased expression of TGFβ1 and hypoxia-inducible factor-1α (HIF1α) in GSCs. At the molecular level, POSTN regulated invasion and expression of EMT (caveolin-1) and angiogenesis-related genes (HIF1α and VEGF-A) through activation of STAT3. Moreover, recombinant POSTN increased GSC invasion. Collectively, our findings suggest that POSTN plays an important role in glioma invasion and resistance to antiangiogenic therapy. Mol Cancer Ther; 15(9); 2187-97. ©2016 AACR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.